Cadrenal Therapeutics Patents – Insights and Stats (Updated 2024)

Cadrenal Therapeutics has a total of 7 patents globally, out of which 5 have been granted. Of these 7 patents, all patents are inactive. The United States of America is where Cadrenal Therapeutics has filed all their patents. Parallelly, United States of America seems to be the main focused R&D centre and also is the origin country of Cadrenal Therapeutics.

Cadrenal Therapeutics was founded in 2022. Cadrenal Therapeutics is working on a new treatment called tecarfarin. It’s aimed at preventing blood clots in people with kidney disease who are on dialysis and have irregular heartbeats. Tecarfarin works differently from other drugs used for this purpose.

Do read about some of the most popular patents of Cadrenal Therapeutics which have been covered by us in this article and also you can find Cadrenal Therapeutics patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Cadrenal Therapeutics patent portfolio.

How many patents does Cadrenal Therapeutics have?

Cadrenal Therapeutics has a total of 7 patents globally. These patents belong to 2 unique patent families. Out of 7 patents, all the patents are inactive.

How Many Patents did Cadrenal Therapeutics File Every Year?

Cadrenal Therapeutics Patent Filing Trend

Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.

Year of Patents Filing or GrantCadrenal Therapeutics Applications FiledCadrenal Therapeutics Patents Granted

How many Cadrenal Therapeutics patents are Alive/Dead?

All the Cadrenal Therapeutics patents are dead.

How Many Patents did Cadrenal Therapeutics File in Different Countries?

Cadrenal Therapeutics filled all their patents in United States of America.

Where are Research Centers of Cadrenal Therapeutics Patents Located?

The Research Center of Cadrenal Therapeutics Patents is the United States of America.

What Percentage of Cadrenal Therapeutics US Patent Applications Were Granted?

Cadrenal Therapeutics (Excluding its subsidiaries) has filed 4 patent applications at USPTO so far (Excluding Design and PCT applications). Out of these 2 have been granted leading to a grant rate of 50%.

Below are the key stats of Cadrenal Therapeutics patent prosecution at the USPTO.

Which Law Firms Filed Most US Patents for Cadrenal Therapeutics?

Law FirmTotal ApplicationsSuccess Rate
Cooley Llp2100%
Wood Phillips Katz Clark & Mortimer10%

List of Cadrenal Therapeutics Patents

Cadrenal Therapeutics PatentTitle
US20170112858A1Extended Release Aspirin
US20170112857A1Extended Release Aspirin
US7932405B2Halogenated Ester Derivatives Of Coumarins For The Treatment Of Coagulation Disorders
US7666902B2Haloalkyl Ester Derivatives Of Coumarin For The Treatment Of Coagulation Disorders
US7285671B2Materials And Methods For Treating Coagulation Disorders
US7253208B2Materials And Methods For Treating Coagulation Disorders
US7145020B2Materials And Methods For Treating Coagulation Disorders

What are Cadrenal Therapeutics key innovation segments?

What Technologies are Covered by Cadrenal Therapeutics?

The chart below distributes patents filed by Cadrenal Therapeutics in different countries on the basis of the technology protected in patents. It also represents the markets where Cadrenal Therapeutics thinks it’s important to protect particular technology inventions.

R&D Focus: How has Cadrenal Therapeutics search focus changed over the years?


Interested in knowing about the areas of innovation that are being protected by Cadrenal Therapeutics?

Related Articles

Was this article helpful?

Leave a Comment

Fill the form to get the details:

Our comprehensive report provides an in-depth look into the patent portfolio. The report includes a breakdown of the patent portfolio across various technologies, listing the patent along with brief summaries of each patent's technology.